Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Trastuzumab Rezetecan and Adebrelimab for HER2-positive Muscle-invasive Bladder Cancer: a Phase II, Prospective, Single-arm, Multicenter Trial

NCT07624201 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT07624201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07624201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Trastuzumab Rezetecan and Adebrelimab for HER2-positive Muscle-invasive Bladder Cancer: a Phase II, Prospective, Single-arm, Multicenter Trial
Lead sponsor
Harbin Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
June 1, 2029
Enrollment
58 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

muscle-invasive bladder cancer (mibc)